Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine + dexmedetomidine for prevention of chronic postsurgical pain after pancreatic surgery
ChiCTR2600135385Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine and dexmedetomidine in Persistent postsurgical pain (PPSP) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Chronic pain. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
esketaminedexmedetomidine
03
Conditions
Persistent postsurgical pain (PPSP)
Beyond the preview
Go deeper on ChiCTR2600135385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135385.